IRONWOOD PHARMACEUTICALS INC
IRWD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IRWD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IRWD
Ironwood Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal (GI) diseases, with its primary marketed product linaclotide (LINZESS) and a late-stage pipeline candidate apraglutide for short bowel syndrome.
Key risk: Apraglutide approval delay
BioSniper Score
Based on 6 of 6 signals
Market Cap
$682.4M
Cash Runway
—
Lead Asset
apraglutide (Phase 3)
Next Catalyst
Patent_Expiry · Aug 16, 2033Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 catalyst for IRONWOOD PHARMACEUTICALS INC.
Similar companies
Ironwood Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal (GI) diseases, with its primary marketed product linaclotide (LINZESS) and a late-stage pipeline candidate apraglutide for short bowel syndrome.
- Ironwood's primary revenue source is linaclotide (LINZESS), approved for IBS-C and chronic idiopathic constipation in the U.S., with partnerships including AbbVie, AstraZeneca, and Astellas [sec_mda · as of 2026-02-26].
- The company reported total revenue of $113.0M and net income of $51.3M for the six months ended June 30, 2026, with cash and equivalents of $79.1M as of that date [sec].
- Apraglutide, a next-generation GLP-2 analog for short bowel syndrome, showed positive topline Phase III results in February 2024, but the FDA indicated in April 2025 that a confirmatory Phase III trial is needed for approval [sec_mda · as of 2025-05-12].
- Ironwood has a negative shareholders' equity of -$261.8M as of June 30, 2026, reflecting accumulated deficits and debt obligations [sec].
- The company expects its cash, operating inflows, and revolving credit facility to fund operations for at least the next twelve months from June 30, 2026 [sec_mda · as of 2026-08-06].
What works
- Linaclotide is a well-established commercial product with broad partnerships (AbbVie, AstraZeneca, Astellas) supporting global development and commercialization [sec_mda · as of 2026-02-26].
- Apraglutide has positive Phase III data in short bowel syndrome, addressing a high unmet need for patients dependent on parenteral support [sec_mda · as of 2026-02-26].
- The company maintains a disciplined investment approach, funding pipeline stages only upon receipt of clear, supportive data [sec_mda · as of 2026-08-06].
What to weigh
- The FDA has required a confirmatory Phase III trial for apraglutide, delaying potential approval and revenue generation [sec_mda · as of 2025-05-12].
- Ironwood has negative shareholders' equity of -$261.8M as of June 30, 2026, indicating accumulated losses exceeding equity [sec].
- The company faces uncertainty in expanding linaclotide's indications and in the timing of apraglutide's regulatory approval and commercialization [sec_mda · as of 2026-05-07].
- Substantial expenses are expected to continue for several years as the company develops and commercializes its pipeline, with no guarantee of positive cash flows [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Linaclotide is partnered with major pharmaceutical companies globally.
“We have strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world, including with AbbVie in the U.S. and all countries worldwide other than China (including Hong Kong and Macau) and Japan, AstraZeneca in China (including Hong Kong and Macau), and Astellas in Japan.”
SEC MD&A · February 26, 2026
Apraglutide requires a confirmatory Phase III trial per FDA feedback.
“based on feedback received from the U.S. FDA in April 2025, a confirmatory Phase III trial is needed to seek approval for apraglutide.”
SEC MD&A · May 12, 2025
Catalyst timeline
- 2033-08-16 · Patent_Expiry · LINZESS — Patent/exclusivity expiry for LINZESS could allow generic competition, impacting linaclotide revenue.
Risks & what to watch (4)›
Key risks
- Apraglutide approval delay — FDA requires a confirmatory Phase III trial for apraglutide, pushing back potential approval and revenue [sec_mda · as of 2025-05-12].
- Negative shareholders' equity — Shareholders' equity of -$261.8M as of June 30, 2026 indicates accumulated deficits and financial leverage [sec].
- Dependence on linaclotide revenue — Linaclotide is the primary revenue source; any decline or loss of exclusivity would materially impact finances [sec_mda · as of 2026-08-06].
- Uncertain pipeline expansion — Expanding linaclotide's indications or developing new candidates is uncertain and costly [sec_mda · as of 2026-05-07].
What to watch
- FDA feedback and initiation of confirmatory Phase III trial for apraglutide [sec_mda · as of 2025-05-12].
- Linaclotide patent expiry on August 16, 2033, which could open the door to generic competition [upcoming catalysts].
- Cash runway and ability to maintain positive cash flows from operations [sec_mda · as of 2026-08-06].
- Progress in expanding linaclotide's approved indications or geographic reach [sec_mda · as of 2026-02-26].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run IRONWOOD PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IRONWOOD PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
OCF $58M · Net income $51M
Lead: Approved
2 candidates
1 upcoming, next in ~2543d
0 buys · 4 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
224
Total value held
$599.1M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 15,028,000 | $52.7M |
| blackrock, inc. | 13,362,930 | $46.9M |
| vanguard capital management llc | 12,194,908 | $42.8M |
| ubs group ag | 12,133,545 | $42.6M |
| sarissa capital management lp | 9,188,635 | $32.3M |
| bank of america corp /de/ | 8,682,907 | $30.5M |
| renaissance technologies llc | 8,061,073 | $28.3M |
| aqr capital management llc | 7,535,080 | $26.4M |
| state street corp | 7,456,944 | $26.2M |
| vanguard portfolio management llc | 6,682,037 | $23.5M |
Showing top 10 of 224 institutional holders of IRONWOOD PHARMACEUTICALS INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 11.5%
- Days to cover
- 9.6
- Shares short
- 17,266,421
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IRWD short interestGovernance
Frequently asked questions
What is the AI investment thesis for IRONWOOD PHARMACEUTICALS INC?
Ironwood Pharmaceuticals is a commercial-stage biopharmaceutical company focused on gastrointestinal (GI) diseases, with its primary marketed product linaclotide (LINZESS) and a late-stage pipeline candidate apraglutide for short bowel syndrome.
What is IRONWOOD PHARMACEUTICALS INC's lead drug candidate?
IRONWOOD PHARMACEUTICALS INC's most advanced tracked candidate is apraglutide (Phase 3) for short bowel syndrome with intestinal failure (SBS-IF).
What is IRONWOOD PHARMACEUTICALS INC's next catalyst?
IRONWOOD PHARMACEUTICALS INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: LINZESS" — expected August 16, 2033.
Who is the CEO of IRONWOOD PHARMACEUTICALS INC?
Mr. Thomas A. McCourt is the chief executive officer of IRONWOOD PHARMACEUTICALS INC (IRWD).
Where is IRONWOOD PHARMACEUTICALS INC headquartered?
IRONWOOD PHARMACEUTICALS INC (IRWD) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.